Uncover key drivers, emerging technologies, and competitive movements shaping the dry age related macular degeneration (amd) market from 2026–2035 with trusted insights from The Business Research Company
What long-term size projections exist for the Dry Age Related Macular Degeneration (AMD) Market covering 2026–2035?
The dry age related macular degeneration (amd) market size has demonstrated substantial growth in recent years. This market is projected to expand from $4.89 billion in 2025 to $5.32 billion in 2026, at a compound annual growth rate (CAGR) of 8.8%. Historically, this expansion can be attributed to factors such as an aging population, the increase in ophthalmology clinic facilities, the adoption of vitamin-based therapies, advancements in retinal imaging techniques, and greater public awareness of vision loss.
The market for dry age-related macular degeneration (AMD) is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach $7.36 billion, demonstrating a compound annual growth rate (CAGR) of 8.5%. This projected increase during the forecast period is attributable to several factors, including the development of new therapeutic pipelines, advancements in precision ophthalmology, AI-driven retinal diagnostics, the implementation of preventive eye care initiatives, and increased investments in clinical trials. Key trends influencing the forecast period encompass a heightened emphasis on detecting the disease early, a rise in the application of nutritional supplement treatments, expanded research into disease-modifying medications, a growing embrace of sophisticated retinal imaging techniques, and improved patient understanding and screening efforts.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21176&type=smp
Which Drivers Are Impacting The Competitive Landscape Of The Dry Age Related Macular Degeneration (AMD) Market?
The expansion of the elderly demographic is anticipated to fuel the progression of the dry age-related macular degeneration (AMD) market. This demographic, comprising individuals 65 years and older, undergoes physiological changes associated with aging, leading to a heightened demand for healthcare and vision-care services. The global increase in the geriatric population is attributed to factors such as longer life expectancy, enhanced management of chronic diseases, breakthroughs in medical technology, and broader availability of specialized care for the elderly across the globe. The dry age-related macular degeneration (AMD) market aligns with this trend by providing specific therapies and management approaches designed to decelerate retinal degeneration and maintain vision for older individuals. As an illustration, in July 2023, data from the United Nations, a US-based intergovernmental organization, indicated that the worldwide population aged 65 and above stood at 0.77 billion in 2022, with projections showing it will near 1.0 billion by 2030. Consequently, the increasing number of older adults is propelling the expansion of the dry age-related macular degeneration (AMD) market.
What Leading Segments Are Studied In The Dry Age Related Macular Degeneration (AMD) Market?
The dry age related macular degeneration (amd) market covered in this report is segmented –
1) By Stages: Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration
2) By Age Group: Above 75 Years, Above 60 Years, Above 40 Years
3) By Route Of Administration: Oral, Injectables
4) By End Users: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes
Subsegments:
1) By Early Age-Related Macular Degeneration: Drusen Accumulation, Retinal Pigment Epithelium Changes
2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits, Increased Pigmentary Abnormalities
3) By Late Age-Related Macular Degeneration: Geographic Atrophy, Central Vision Loss
Which Market Trends Are Opening Growth Opportunities In The Dry Age Related Macular Degeneration (AMD) Market?
Leading companies within the dry age-related macular degeneration (AMD) market are prioritizing the development of sophisticated technologies, such as light delivery systems, to stimulate retinal cells, enhance visual function, and potentially decelerate disease progression. These light delivery systems are therapeutic devices designed to provide controlled wavelengths of light to specific retinal tissues, activating cellular processes and promoting retinal health through non-invasive photobiomodulation techniques. For example, in January 2024, LumiThera Inc., a US-based medical device company, introduced photobiomodulation therapy for dry AMD using the Valeda Light Delivery System, marking it as the first FDA-authorized treatment for vision loss associated with dry AMD. The system employs a multi-wavelength light delivery method, utilizing 590 nm, 660 nm, and 850 nm wavelengths to stimulate retinal cells, and LumiThera has launched the EUROLIGHT registry study to collect long-term outcome data, with treatments typically provided in nine sessions across a three- to four-week period.
Which Major Industry Participants Are Leading The Dry Age Related Macular Degeneration (AMD) Market Growth?
Major companies operating in the dry age related macular degeneration (amd) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Apellis Pharmaceuticals Inc., Belite Bio Inc., Alkeus Pharmaceuticals Inc., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc., Regeneron Pharmaceuticals Inc., Annexon Biosciences Inc., Stealth BioTherapeutics Corp., Kodiak Sciences Inc., Ionis Pharmaceuticals Inc., Lineage Cell Therapeutics Inc., Ocular Therapeutix Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Is Expected To Experience The Fastest Growth In The Dry Age Related Macular Degeneration (AMD) Market?
North America was the largest region in the dry age-related macular degeneration (AMD) market in 2025. The regions covered in the dry age related macular degeneration (amd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Dry Age Related Macular Degeneration (AMD) Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21176&type=smp
Browse Through More Reports Similar to the Global Dry Age Related Macular Degeneration (AMD) Market 2026, By The Business Research Company
Non Proliferative Diabetic Retinopathy Market Report 2026
Macular Degeneration Treatment Market Report 2026
Macular Edema And Macular Degeneration Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model